Evidence map›Paper›PMID 34307977›Full record

ArticleKidney international reports2021

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.

Chaim Charytan, Roberto Manllo-Karim, Edouard R Martin, Dylan Steer, Marializa Bernardo, Sohan L Dua, Moustafa A Moustafa, Gopal Saha, Charles Bradley, Meraf Eyassu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 13 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 13 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Chaim CharytanNephrology Associates, PC, Queens, New York, USA.
Roberto Manllo-KarimSouth Texas Kidney Specialists, PA, McAllen, Teas, USA.
Edouard R MartinSouth Florida Nephrology Associates, Lauderdale Lakes, Florida, USA.
Dylan SteerBalboa Nephrology Medical Group, La Jolla, California, USA.
Marializa BernardoSouthwest Nephrology Associates, Houston, Texas, USA.
Sohan L DuaValley Renal Medical Group, Northridge, California, USA.
Moustafa A MoustafaSouth Carolina Nephrology & Hypertension Center, Inc., Orangeburg, South Carolina, USA.
Gopal SahaFibroGen, Inc., San Francisco, California, USA.
Charles BradleyFibroGen, Inc., San Francisco, California, USA.
Meraf EyassuFibroGen, Inc., San Francisco, California, USA.
Robert LeongFibroGen, Inc., San Francisco, California, USA.
Khalil G SaikaliFibroGen, Inc., San Francisco, California, USA.
Cameron LiuFibroGen, Inc., San Francisco, California, USA.
Lynda SzczechFibroGen, Inc., San Francisco, California, USA.
Kin-Hung P YuFibroGen, Inc., San Francisco, California, USA.
FibroGen (United States) · USBalboa Nephrology Medical Group · USDallas Nephrology Associates · USFlorida Urology Associates · USKidney Associates · USUrology Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionErythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis.

methodsSIERRAS was a phase 3, randomized, open-label, active-controlled study enrolled adults on dialysis for end-stage kidney disease receiving erythropoiesis-stimulating agents for anemia. Patients were randomized (1:1) to thrice-weekly roxadustat or epoetin alfa. Doses were based on previous epoetin alfa dose and adjusted in the roxadustat arm to maintain hemoglobin at ∼11 g/dl during treatment. Epoetin alfa dosing was adjusted per US package insert. Primary efficacy endpoint was mean hemoglobin (g/dl) change from baseline averaged over weeks 28 to 52. Treatment-emergent adverse events were monitored.

resultsEnrolled patients (roxadustat,

conclusionIn end-stage kidney disease, roxadustat was noninferior to epoetin alfa in up to 52 weeks of treatment in this erythropoietin-stimulating agent conversion study. Roxadustat had an acceptable tolerability profile.

Indexed as

dialysisepoetin alfahemoglobinkidney failureroxadustat

Identifiers

PMID34307977
PMCPMC8258588
OpenAlexW3155430778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.